Immutep (Formerly known as Prima Biomed)
Unit 7, 79 - 83 High Street
Melbourne
Victoria
3101
United States
Tel: 61-3-9854-5700
Fax: 61-3-9854-5777
Website: http://www.primabiomed.com.au/
Email: enquiries@primabiomed.com.au
263 articles about Immutep (Formerly known as Prima Biomed)
-
Immutep Announces First Clinical Data from 90mg Dosing of Efti
3/5/2024
Immutep Limited today announces safety and initial efficacy data from the first ever 90mg dosing of eftilagimod alpha (efti) in combination with weekly paclitaxel in patients from the safety lead-in (N=6) of the AIPAC-003 Phase II/III trial.
-
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer
1/4/2024
Immutep Limited today announces that the first patient has been enrolled and safely dosed in the INSIGHT-005 Phase I trial.
-
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
12/7/2023
Immutep Limited is pleased to announce it has received a €1,595,475 research and development tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme.
-
Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
11/22/2023
Immutep Limited today announces that the INSIGHT-003 trial has been expanded to four sites across Germany including the University Clinic of Ruhr Universität Bochum and the Lung Clinic Cologne-Merheim.
-
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
11/9/2023
Immutep Limited announces the completion of patient enrollment in the TACTI-003 Phase IIb trial evaluating eftilagimod alpha, its proprietary soluble LAG-3 protein and MHC Class II agonist, in combination with MSD’s anti-PD-1 therapy KEYTRUDA® as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma.
-
Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer
11/6/2023
Immutep Limited today announces the open-label safety lead-in of its integrated AIPAC-003 Phase II/III trial evaluating for the very first time 90mg of eftilagimod alpha (efti) in combination with paclitaxel has been completed with no safety or tolerability issues.
-
Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer
11/3/2023
Immutep Limited announces new biomarker data from the TACTI-002/KEYNOTE-798 Phase II trial evaluating eftilagimod alpha, a soluble LAG-3 protein and first-in-class MHC Class II agonist administered subcutaneously, in combination with MSD’s anti-PD-1 therapy KEYTRUDA® as first-line treatment for patients with previously untreated unresectable or metastatic non-small cell lung cancer.
-
Immutep to Participate in November 2023 Investor Events
11/2/2023
Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announces its management will participate in the following upcoming investor events in November.
-
Immutep Quarterly Activities Report Q1 FY24
10/31/2023
Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha and IMP761 for the quarter ended 30 September 2023.
-
Immutep receives ~A$1.13 million R&D Tax Incentive
10/25/2023
Immutep Limited, is pleased to announce that it has received a A$1,134,882 cash rebate from the Australian Federal Government’s R&D tax incentive program.
-
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
10/24/2023
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today provides an overview of the promising clinical data from the investigator-initiated INSIGHT-003 trial.
-
Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use
9/21/2023
Immutep Limited announces the regulatory authorization of eftilagimod alpha manufactured at commercial 2,000L scale for use in clinical trials across multiple European countries including Germany, Belgium, Denmark, and the United Kingdom.
-
Immutep to Participate in September 2023 Investor Conferences
9/5/2023
Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announces its management will participate in the following upcoming investor conferences in September.
-
Immutep Receives Positive Scientific Advice from European Medicines Agency
8/1/2023
Immutep Limited today announces it has received positive scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the continued development of eftilagimod alpha (efti).
-
Immutep Quarterly Activities Report Q4 FY23
7/31/2023
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, provides an update on the ongoing development of its product candidates, eftilagimod alpha (efti) and IMP761 for its fiscal fourth quarter ended 30 June 2023 (Q4 FY23).
-
First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma
7/28/2023
Immutep Limited today announces the first patient has been enrolled and safely dosed in EFTISARC-NEO, the Phase II investigator-initiated trial of eftilagimod alpha (efti).
-
Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor
6/27/2023
Immutep Limited today announced the grant of a new patent (number 11,684,654) entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent Office.
-
Immutep Completes A$80 Million Capital Raise
6/27/2023
Immutep Limited today announces the successful completion of an A$80 million capital raise to support its late-stage and expanding clinical development pipeline.
-
Immutep to Participate at the Jefferies Healthcare Conference
6/7/2023
Immutep Limited today announces Marc Voigt, CEO of Immutep, will be presenting at the Jefferies Healthcare Conference being held on June 7-9, 2023 in New York City, NY.
-
Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer
6/2/2023
Immutep Limited is pleased to announce the successful completion of an institutional placement and the institutional component of its 1 for 7.6 pro rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Immutep.